Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer
NCT04862780 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer
- Lead sponsor
- Blueprint Medicines Corporation
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- June 29, 2021
- Completion date
- October 7, 2024
- Enrollment
- 177 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, antineoplastic agents, bronchial neoplasms, carcinoma, carcinoma, bronchogenic, carcinoma, non-small-cell lung, egf-r positive non-small cell lung cancer, egfr activating mutation, egfr c797s, egfr exon 19 deletion, egfr gene mutation, egfr l858r, egfr mutation resulting in tyrosine kinase inhibitor resistance, egfr t790m, lung diseases, lung neoplasms, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, nerve tissue, protein kinase inhibitors, respiratory tract disease, respiratory tract neoplasms, thoracic neoplasms